IWel Health Announces Addition of Former FDA Deputy Commissioner Dr. Michael A Friedman to Its Scientific Board

IWel Health announces addition of Michael A Friedman, MD, to its Scientific Board.

Dr. Friedman is an experienced healthcare leader with a distinguished career in oncology research, regulatory strategy, and public healthcare policy.  He served as President and CEO of City of Hope, a leading cancer research, treatment and education institution.  Before that, Dr. Friedman was SVP of R&D, Medical and Public policy for Pharmacia Corp (acquired by Pfizer).  Dr. Friedman previously served as deputy commissioner for the U.S. FDA, later serving as acting commissioner.  Dr. Friedman holds a MD degree from the University of Texas and received his bachelor’s degree from Tulane University.

Dr. Friedman currently serves on the board of Mannkind, Cytovia, Sermonix and as a trustee of Tulane University and on the California Stem Cell Oversight Board.  He has served as a nonexecutive director on the boards of the Celgene, Smith and Nephew, and Intuitive Surgical.

IWel Health develops and manufactures biosensing products including continuous glucose monitoring products for medical and wellness applications. Its manufacturing facility is based in Exton, PA.

Scroll to Top